Effect of astragaloside IV on the embryo-fetal development of Sprague-Dawley rats and New Zealand White rabbits.
Astragaloside IV, a natural product purified from the Chinese medicinal herb Astragalus membranaceus (Fisch) Bge, is now being developed as a cardioprotective agent for treating cardiovascular diseases. In the present study developmental toxicity of astragaloside IV in Sprague-Dawley rats and New Zealand White rabbits was evaluated by intravenously administering astragaloside IV daily to rats at 0.25, 0.5 and 1.0 mg kg(-1) on gestation days 6-15, and to rabbits at 0.5, 1.0 and 2.0 mg kg(-1) daily on gestation days 6-18. Reproductive parameters were determined and fetuses were examined for external, visceral and skeletal malformations. There was significant difference in total weight gain during and after treatment between the control group and 1.0 mg kg(-1) group in rats. The percentage of fetal deaths in 0.5 and 1.0 mg kg(-1) rat groups was significantly higher than that of the control group, and higher in all treatment groups than in the control in rabbits. These results indicated that astragaloside IV was maternally toxic at 1.0 mg kg(-1) in rats and fetotoxic at a dose higher than 0.5 mg kg(-1), but devoid of teratogenic effects in rats and rabbits. In light of these findings it is perhaps prudent to advise caution to women who might use astragaloside IV to combat cardiovascular disease during pregnancy.
Jiangbo
Zhu
Z
Department of Toxicology, Second Military Medical University, Shanghai, People's Republic of China. toxiboy2001@yahoo.com.cn
Xuying
Wan
W
Yuping
Zhu
Z
Xili
Ma
M
Yiwen
Zheng
Z
Tianbao
Zhang
Z
D000014:Abnormalities, Drug-Induced / Q000196:embryology / Q000209:etiology; D000818:Animals; D002316:Cardiotonic Agents / Q000009:adverse effects* / Q000302:isolation & purification; D004305:Dose-Response Relationship, Drug; D004365:Drugs, Chinese Herbal / Q000009:adverse effects* / Q000302:isolation & purification; D047108:Embryonic Development / Q000187:drug effects*; D005260:Female; D047109:Fetal Development / Q000187:drug effects*; D005865:Gestational Age; D008297:Male; D008516:Medicine, Chinese Traditional; D011247:Pregnancy; D011817:Rabbits; D051381:Rats; D017207:Rats, Sprague-Dawley; D012503:Saponins / Q000009:adverse effects* / Q000302:isolation & purification; D014315:Triterpenes / Q000009:adverse effects* / Q000302:isolation & purification
D002316:Cardiotonic Agents; D004365:Drugs, Chinese Herbal; D012503:Saponins; D014315:Triterpenes; C052064:astragaloside A